DLB (n = 92) | PDD (n = 93) | x2/Z-score | P-value | |
---|---|---|---|---|
Gender, n (%) | 0.046 | 0.830 | ||
Male | 50 (54.3%) | 52 (55.9%) | ||
Female | 42 (45.7%) | 41 (44.1%) | ||
Age at visit, years, median (IQR) | 71 (66,78) | 67 (62,74) | −3.900 | 0.000 |
Age at onset, years, median (IQR) | 69 (63,75) | 63 (59,71) | −3.456 | 0.001 |
Education, years, median (IQR) | 9 (9,15) | 9 (6,12) | −2.142 | 0.032 |
Marital status, n (%) | 0.144 | 0.705 | ||
Married | 67 (72.8%) | 70 (75.3%) | ||
Widowed | 20 (21.7%) | 23 (24.7%) | ||
Divorced | 1 (1.1%) | 0 (0.0%) | ||
Single | 4 (4.3%) | 0 (0.0%) | ||
Smoking, yes, n (%) | 25 (27.2%) | 20 (21.5%) | 0.807 | 0.369 |
Alcohol consumption, yes, n (%) | 20 (21.7%) | 15 (16.1%) | 0.949 | 0.330 |
Cardiometabolic conditions, n (%) | ||||
Heart disease | 21 (22.8%) | 31 (33.3%) | 2.527 | 0.112 |
Hypertension | 30 (32.6%) | 16 (17.2%) | 5.874 | 0.015 |
DM | 22 (23.9%) | 10 (10.8%) | 5.599 | 0.018 |
Stroke | 12 (13.0%) | 8 (8.6%) | 0.946 | 0.331 |
APOE genotype frequency, n (%) | ||||
2/2 | 1 (1.1%) | 2 (2.2%) | 0.328 | 1.000 |
2/3 | 3 (3.3%) | 8 (8.6%) | 2.359 | 0.212 |
2/4 | 0 (0.0%) | 1 (1.1%) | 0.995 | 1.000 |
3/3 | 35 (38. 0%) | 71 (76.3%) | 27.728 | 0.000 |
3/4 | 51 (55.4%) | 10 (10.8%) | 41.779 | 0.000 |
4/4 | 2 (2.2%) | 1 (1.1%) | 0.350 | 0.621 |
APOE allele frequency, n (%) | ||||
ε2 | 5 (2.7%) | 13 (7.0%) | 3.647 | 0.056 |
ε3 | 124 (67. 4%) | 160 (86.0%) | 17.995 | 0.000 |
ε4 | 55 (29.9%) | 13 (7.0%) | 32.342 | 0.000 |
APOE ε4 carriers, n (%) | 40.557 | 0.000 | ||
Yes | 53 (57.6%) | 12 (12.9%) | ||
No | 39 (42.4%) | 81 (87.1%) | ||
Drug prescriptions, n (%) | ||||
ChEIs | 63 (68.5%) | 9 (9.7%) | 67.266 | 0.000 |
Anti-Parkinsonism | 11 (12.0%) | 50 (53.8%) | 36.575 | 0.000 |
Antipsychotics | 18 (19.6%) | 3 (3.2%) | 12.270 | 0.000 |
Core features, n (%) | ||||
FLC | 26 (28.3%) | 9 (9.7%) | 10.412 | 0.001 |
VH | 44 (47.8%) | 13 (14.0%) | 24.855 | 0.000 |
Parkinsonism | 44 (47.8%) | 93 (100.0%) | 54.914 | 0.000 |
RBD | 51 (55.4%) | 21 (22.6%) | 21.000 | 0.000 |